PACLA MEDICAL LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +103.1%

  £93,346 → £189,551

• Cash

  -70.5%

  £62,912 → £18,564

• Net assets

  -123.2%

  -£358,817 → -£800,791

  lowest in 6 filed years

• Employees

  0%

  6 → 6

• Operating profit

  +50.2%

  -£1,412,610 → -£703,901

• Profit before tax

  +48.2%

  -£1,440,424 → -£745,887

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

FRS 102 §1A

Reporting scope

Consolidated group

Abridged

Yes — abridged accounts (limited disclosure)

Audit opinion

Unaudited (audit-exempt)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis. The directors have considered the company's results and financial condition and have concluded that there are no material uncertainties that would cast significant doubt on the company's ability to continue as a going concern.”

Group structure

1. PACLA MEDICAL LIMITED · parent
   1. Pacla Medical Inc. 100% · USA (Delaware)

Significant events

• “The Company is raising a Bridging Round from existing and new angel investors, which our US strategic advisor is introducing to investors in his US network. We are in advanced discussions with two US venture capital funds to raise a Series A round, with targeted close in October 2025.”
• “The Company has made substantial progress in developing a more robust version of the BackHug (V4). The Company is uncertain of the timing of the release of the V4 and, after its release, the extent and timeline over which it will replace the V3 BackHug units currently on subscription with customers. Notwithstanding this uncertainty, the Company believes that, over time, all or a significant proportion of the installed base of V3 BackHugs will be replaced by V4 BackHugs, with a high likelihood that a significant proportion will be replaced in the short term. Accordingly, the Company believes that the value of the V3 BackHug units currently on subscription with customers is subject to considerable uncertainty and that it should be valued substantially below cost due to the high likelihood that a significant proportion of them will be written down to zero value in the short term when they are replaced with V4 BackHugs.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

12

last 12 months

Capital events

8

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.